Effects of donepezil 23 mg on Severe Impairment Battery domains in patients with moderate to severe Alzheimer's disease: evaluating the impact of baseline severity

INTRODUCTION: The US Food and Drug Administration approved a 23 mg daily dose of donepezil for treatment of moderate to severe Alzheimer's disease (AD) based on outcomes from a large trial comparing the 23 mg/day dose with the standard 10 mg/day dose. Results from this study indicated that afte...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Ferris, Steven, Cummings, Jeffrey, Christensen, Daniel, Doody, Rachelle, Farlow, Martin, Sabbagh, Marwan, Liu, Liang, Mackell, Joan, Fain, Randi
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2013
Assuntos:
Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4055003/
https://ncbi.nlm.nih.gov/pubmed/23433097
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/alzrt166
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados